在青少年皮肤肌炎中有前途的治疗方法
Belina Y Yi1, Mercy Joyce2, Ross Gilbert3
1Division of Pediatric Allergy, Immunology, and Rheumatology, Department of Pediatrics, Johns Hopkins University School of Medicine, 600 North Wolfe Street, Blalock 430, Baltimore, MD 21287, USA.
Rheumatic diseases clinics of North America
|October 29, 2025
概括
青少年皮肤肌肉炎 (JDM) 治疗结合了抗炎药物和非药物治疗. 新兴的治疗方法,如Janus激酶抑制剂,为控制这种自身免疫性疾病提供了新的希望.
科学领域:
- 儿科风湿病学 儿科风湿病学
- 免疫学 免疫学 免疫学
- 自免疫性疾病 自免疫性疾病
背景情况:
- 青少年皮肤肌炎 (JDM) 是一种罕见的自身免疫性疾病,影响结缔组织.
- 它需要包括药理和非药理干预的综合管理策略.
研究的目的:
- 审查JDM目前的治疗方式.
- 突出对JDM管理有前途的新兴疗法.
主要方法:
- 对当前JDM治疗方法的文献综述.
- 既定和新型治疗方法的总结.
主要成果:
- 目前的JDM治疗包括皮质类固醇,DMARDs,IVIg和类固醇节约剂.
- 非药物干预,如物理治疗和光保护,至关重要.
- 新兴的疗法包括Janus激酶抑制剂,CAR-T细胞和干扰素抑制剂.
结论:
- 联合DM管理需要采用多式联运方式.
- 治疗的进步为JDM患者提供了更好的结果.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
480
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
480
Myocarditis III: Medical Management
168
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
168
Myasthenia Gravis: Overview and Treatment
2.8K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.8K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
425
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
425
Inflammatory Bowel Disease IV: Pharmacological Management
471
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
471
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
478
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
478

